Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Inclusion criteria: * Participants meeting the following criteria could be included: * Male or female between 18 and 60 years old. * Females of childbearing potential should be using one of the following acceptable methods of birth control: * Intrauterine Device in place for at least 60 days prior to the first dose of the study (Visit 1) throughout the study and for 30 days after completion of the study. * Hormonal contraceptives for at least 90 days prior to the first dose of the study (Visit 1) throughout the study, and for 30 days after study completion. * Patients whose weight is greater than 50 kg. * Patients diagnosed with homozygous sickle cell anemia of SS genotype (documented by genotyping). * Patients who have been treated with an anti-sickling agent (Siklos®) within six months of the screening visit (Visit 0) must maintain the therapy continuous and unmodified for at least six months with the intent to continue for the duration of the study. * Patients who are available to attend on an outpatient basis for visits provided for in the protocol and can complete the data collection documents (and quality of life scale). * Patients have given written informed consent. * Patients with a health insurance coverage. Exclusion criteria: * Participants meeting the following criteria could not be included: * Patients with known or suspected allergies to any ingredient of the food supplement (β-NMN, Isomalt, Magnesium stearate, microcrystalline cellulose). * Patients wh…